CD47 and neoplasm: After administration, the Bev + anti-CD47 treatment formulation produced smaller tumour volumes, especially in the Bev (10 mg/kg) + anti-CD47 (20 mg/kg) group (200.24 ± 68.23 mm3), whereas the tumour volumes in the Bev group (492.11 ± 173.67 mm3) and anti-CD47 group (884.56 ± 230.58 mm3) were smaller than those in the tumour PBS group (1,303.75 ± 347.45 mm3) (Figures 3A1–3; Supplementary Table S5).